The Lancet Oncology Q1 Unclaimed
The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 324. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer,. It has an SJR impact factor of 13,53 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 13,53.
The Lancet Oncology focuses its scope in these topics and keywords: cancer, phase, patients, randomised, openlabel, care, advanced, metastatic, multicentre, doubleblind, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2395 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
13,53
SJR Impact factor324
H Index491
Total Docs (Last Year)1722
Total Docs (3 years)6955
Total Refs15824
Total Cites (3 years)575
Citable Docs (3 years)8,90
Cites/Doc (2 years)14,16
Ref/DocOther journals with similar parameters
JAMA oncology Q1
Annals of Oncology Q1
Molecular Cancer Q1
CA - A Cancer Journal for Clinicians Q1
Cancer Discovery Q1
Compare this journals
Aims and Scope
Best articles by citations
New screening test for colorectal cancer gets off to a good start
View moreQuality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial
View moreHousehold surfaces hide secondhand smoke affecting children
View moreAn extra defence against skin cancer?
View moreNature Reviews Cancer online
View moreAustralian cancer survival figures greatly improved
View moreFDA licences imatinib mesylate for CML
View moreInteractive
View moreNew nerve-block analgesia for patients with pancreatic cancer
View moreIntracellular fusion antibodies may be suicide for cancer cells
View moreEPA halts cancer-induced weight loss
View moreAllan van Oosterom, President of the EORTC
View moreAmgen's point of view on epoetins
View moreImproving and maintaining human health
View moreLymphatic entrapment of tumour cells after sentinel lymph-node biopsy for melanoma
View moreCancer Institute at Chennai: a model for resource-poor countries
View moreElectrolysis being trialled for use in liver cancer
View moreCCI-779: a new targeted anticancer agent
View moreWhy do hypoxic cells behave badly?
View moreCorrelation of MRI/PET rim enhancement in breast cancer: a delivery related phenomenon with therapy implications?
View moreLow susceptibility genes for breast cancer: the way forward?
View moreOncology and the media
View moreOncology and the media
View moreIs red tape stifling the progress of new anticancer drugs?
View more
If you are a journal editor you can claim the journal profile and add new information for the visitors.
Comments